Incidence and Clinical Significance of De Novo Donor Specific Antibodies after Kidney Transplantation
Kidney transplantation has evolved over more than half a century and remarkable progress has been made in patient and graft outcomes. Despite these advances, chronic allograft dysfunction remains a major problem. Among other reasons, de novo formation of antibodies against donor human leukocyte anti...
Saved in:
Main Authors: | Sophia Lionaki, Konstantinos Panagiotellis, Aliki Iniotaki, John N. Boletis |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2013/849835 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of de novo donor specific antibodies after kidney transplantation in the era of donor-derived cell-free DNA
by: Yuan Tian, et al.
Published: (2025-01-01) -
De Novo Donor-Specific HLA Antibody Development and Peripheral CD4+CD25high Cells in Kidney Transplant Recipients: A Place for Interaction?
by: Josefina Alberu, et al.
Published: (2012-01-01) -
Clinical Outcomes and Donor-specific Antibody Rebound 5 y After Kidney Transplant Enabled by Imlifidase Desensitization
by: Ian S. Jaffe, BS, et al.
Published: (2025-02-01) -
Significance of Semiquantitative Assessment of Preformed Donor-Specific Antibody Using Luminex Single Bead Assay in Living Related Liver Transplantation
by: Atsushi Yoshizawa, et al.
Published: (2013-01-01) -
Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study
by: Zhiliang Guo, et al.
Published: (2025-01-01)